CN104411684B - 苯氧基乙基哌啶化合物 - Google Patents
苯氧基乙基哌啶化合物 Download PDFInfo
- Publication number
- CN104411684B CN104411684B CN201380034168.8A CN201380034168A CN104411684B CN 104411684 B CN104411684 B CN 104411684B CN 201380034168 A CN201380034168 A CN 201380034168A CN 104411684 B CN104411684 B CN 104411684B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- mmol
- mixture
- compounds
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **c1ccc(CNC([C@@]2NCCCC2)=O)cc1 Chemical compound **c1ccc(CNC([C@@]2NCCCC2)=O)cc1 0.000 description 1
- RSUFKEGMFFPMIB-UHFFFAOYSA-N C(COc1ccccc1)N1CCCCC1 Chemical compound C(COc1ccccc1)N1CCCCC1 RSUFKEGMFFPMIB-UHFFFAOYSA-N 0.000 description 1
- DJNCXSGGAMADNN-UHFFFAOYSA-N CC(C)(C)OC(NCc(cc1)ccc1Br)=O Chemical compound CC(C)(C)OC(NCc(cc1)ccc1Br)=O DJNCXSGGAMADNN-UHFFFAOYSA-N 0.000 description 1
- YWAWINJDFPQTNL-UHFFFAOYSA-N O=C(COC1CCCCC1)I Chemical compound O=C(COC1CCCCC1)I YWAWINJDFPQTNL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665951P | 2012-06-29 | 2012-06-29 | |
| US61/665,951 | 2012-06-29 | ||
| US201361779099P | 2013-03-13 | 2013-03-13 | |
| US61/779,099 | 2013-03-13 | ||
| PCT/US2013/046684 WO2014004229A1 (en) | 2012-06-29 | 2013-06-20 | Phenoxyethyl piperidine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104411684A CN104411684A (zh) | 2015-03-11 |
| CN104411684B true CN104411684B (zh) | 2016-08-24 |
Family
ID=48746666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380034168.8A Active CN104411684B (zh) | 2012-06-29 | 2013-06-20 | 苯氧基乙基哌啶化合物 |
Country Status (42)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| KR101807981B1 (ko) | 2013-12-17 | 2017-12-11 | 일라이 릴리 앤드 캄파니 | 페녹시에틸 시클릭 아민 유도체 및 ep4 수용체 조절제로서의 그의 활성 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| PE20191811A1 (es) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| WO2018210987A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| TWI768043B (zh) | 2017-05-18 | 2022-06-21 | 瑞士商愛杜西亞製藥有限公司 | N-取代吲哚衍生物 |
| KR102632028B1 (ko) | 2017-05-18 | 2024-01-31 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 페닐 유도체 |
| ES2995259T3 (en) * | 2019-01-22 | 2025-02-10 | Keythera Suzhou Pharmaceuticals Co Ltd | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005021508A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| CN1950333A (zh) * | 2004-05-04 | 2007-04-18 | 辉瑞大药厂 | 取代的甲基芳基或杂芳基酰胺化合物 |
| CN1950334A (zh) * | 2004-05-04 | 2007-04-18 | 辉瑞有限公司 | 邻位取代的芳基或杂芳基酰胺化合物 |
| WO2008092860A1 (en) * | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Bicyclic derivatives as ep4 agonists |
| CN102026961A (zh) * | 2008-05-14 | 2011-04-20 | 安斯泰来制药株式会社 | 酰胺化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
| MXPA04005555A (es) * | 2002-03-18 | 2005-05-16 | Pfizer Prod Inc | Procedimientos de tratamiento con agonistas selectivos del receptor ep4. |
| KR100752891B1 (ko) * | 2003-01-10 | 2007-08-28 | 에프. 호프만-라 로슈 아게 | 프로스타글란딘 작용제로서 2-피페리돈 유도체 |
| US20050105732A1 (en) * | 2003-11-17 | 2005-05-19 | Hutchings George T. | Systems and methods for delivering pre-encrypted content to a subscriber terminal |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7968578B2 (en) | 2006-04-24 | 2011-06-28 | Merck Frosst Canada Ltd. | Indole amide derivatives as EP4 receptor antagonists |
| US7705035B2 (en) | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
| WO2010019796A1 (en) | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
| BR112012020236A2 (pt) | 2010-02-22 | 2016-05-17 | Raqualia Pharma Inc | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero |
| PE20131343A1 (es) * | 2010-09-21 | 2013-11-18 | Eisai Randd Man Co Ltd | Derivados de acido benzoico |
| EP2729445B1 (en) * | 2011-07-04 | 2015-10-21 | Rottapharm Biotech S.r.l. | Cyclic amine derivatives as ep4 receptor antagonists |
| US9120824B2 (en) * | 2011-07-04 | 2015-09-01 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor agonists |
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
-
2013
- 2013-06-13 JO JOP/2013/0177A patent/JO3296B1/ar active
- 2013-06-13 AR ARP130102076 patent/AR091429A1/es active IP Right Grant
- 2013-06-14 TW TW102121220A patent/TWI599561B/zh active
- 2013-06-20 PT PT137342481T patent/PT2867207T/pt unknown
- 2013-06-20 SI SI201330755T patent/SI2867207T1/sl unknown
- 2013-06-20 EA EA201492255A patent/EA024392B1/ru not_active IP Right Cessation
- 2013-06-20 MX MX2014015953A patent/MX345324B/es active IP Right Grant
- 2013-06-20 EP EP13734248.1A patent/EP2867207B1/en active Active
- 2013-06-20 MY MYPI2014703971A patent/MY173878A/en unknown
- 2013-06-20 PE PE2014002532A patent/PE20150182A1/es active IP Right Grant
- 2013-06-20 JP JP2015520304A patent/JP6127136B2/ja active Active
- 2013-06-20 HR HRP20171515TT patent/HRP20171515T1/hr unknown
- 2013-06-20 CN CN201380034168.8A patent/CN104411684B/zh active Active
- 2013-06-20 WO PCT/US2013/046684 patent/WO2014004229A1/en not_active Ceased
- 2013-06-20 KR KR1020147036137A patent/KR101653476B1/ko active Active
- 2013-06-20 MA MA37686A patent/MA37686B1/fr unknown
- 2013-06-20 DK DK13734248.1T patent/DK2867207T3/en active
- 2013-06-20 CA CA2875569A patent/CA2875569C/en active Active
- 2013-06-20 NZ NZ701933A patent/NZ701933A/en unknown
- 2013-06-20 BR BR112014031616-3A patent/BR112014031616B1/pt active IP Right Grant
- 2013-06-20 HU HUE13734248A patent/HUE034425T2/en unknown
- 2013-06-20 ME MEP-2017-223A patent/ME02840B/me unknown
- 2013-06-20 US US13/922,278 patent/US8962659B2/en active Active
- 2013-06-20 AP AP2014008164A patent/AP2014008164A0/xx unknown
- 2013-06-20 RS RS20171039A patent/RS56452B1/sr unknown
- 2013-06-20 PL PL13734248T patent/PL2867207T3/pl unknown
- 2013-06-20 UA UAA201413598A patent/UA114325C2/uk unknown
- 2013-06-20 SG SG11201408641UA patent/SG11201408641UA/en unknown
- 2013-06-20 ES ES13734248.1T patent/ES2644812T3/es active Active
- 2013-06-20 LT LTEP13734248.1T patent/LT2867207T/lt unknown
- 2013-06-20 AU AU2013280875A patent/AU2013280875B2/en active Active
-
2014
- 2014-11-24 ZA ZA2014/08632A patent/ZA201408632B/en unknown
- 2014-11-27 CO CO14261550A patent/CO7151507A2/es unknown
- 2014-11-28 TN TN2014000501A patent/TN2014000501A1/fr unknown
- 2014-12-03 CR CR20140553A patent/CR20140553A/es unknown
- 2014-12-11 IL IL236219A patent/IL236219A/en active IP Right Grant
- 2014-12-17 GT GT201400288A patent/GT201400288A/es unknown
- 2014-12-17 DO DO2014000287A patent/DOP2014000287A/es unknown
- 2014-12-26 CL CL2014003535A patent/CL2014003535A1/es unknown
- 2014-12-29 EC ECIEPI201433267A patent/ECSP14033267A/es unknown
-
2015
- 2015-01-05 PH PH12015500009A patent/PH12015500009B1/en unknown
- 2015-01-13 US US14/595,350 patent/US9402838B2/en active Active
-
2017
- 2017-09-15 CY CY20171100979T patent/CY1119425T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005021508A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| CN1950333A (zh) * | 2004-05-04 | 2007-04-18 | 辉瑞大药厂 | 取代的甲基芳基或杂芳基酰胺化合物 |
| CN1950334A (zh) * | 2004-05-04 | 2007-04-18 | 辉瑞有限公司 | 邻位取代的芳基或杂芳基酰胺化合物 |
| WO2008092860A1 (en) * | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Bicyclic derivatives as ep4 agonists |
| CN102026961A (zh) * | 2008-05-14 | 2011-04-20 | 安斯泰来制药株式会社 | 酰胺化合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104411684B (zh) | 苯氧基乙基哌啶化合物 | |
| KR101634032B1 (ko) | 디메틸-벤조산 화합물 | |
| CN105209438B (zh) | 苯氧基乙基二氢‑1h‑异喹啉化合物 | |
| HK1203937B (en) | Phenoxyethyl piperidine compounds | |
| HK1203936B (en) | Dimethyl-benzoic acid compounds useful for the treatment of inflammatory conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |